DNA replication forks pause in front of lesions on the template, eventually leading to cytotoxic chromosomal rearrangements. The in vivo structure of damaged eukaryotic replication intermediates has been so far elusive. Combining electron microscopy (EM) and two-dimensional (2D) gel electrophoresis, we found that UV-irradiated S. cerevisiae cells uncouple leading and lagging strand replication at irreparable UV lesions, thus generating long ssDNA regions on one side of the fork. Furthermore, small ssDNA gaps accumulate along replicated duplexes, likely resulting from repriming events downstream of the lesions on both leading and lagging strands. Translesion synthesis and homologous recombination counteract gap accumulation, without affecting fork progression. The DNA damage checkpoint contributes to gap repair and maintains a replication-competent fork structure. We propose that the coordinated action of checkpoint, recombination, and translesion synthesis-mediated processes at the fork and behind the fork preserves the integrity of replicating chromosomes by allowing efficient replication restart and filling the resulting ssDNA gaps.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2005.11.015DOI Listing

Publication Analysis

Top Keywords

irreparable lesions
8
leading lagging
8
ssdna gaps
8
fork
6
replication
5
multiple mechanisms
4
mechanisms control
4
control chromosome
4
chromosome integrity
4
integrity replication
4

Similar Publications

Radiopharmaceuticals and their applications in medicine.

Signal Transduct Target Ther

January 2025

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 100050, Beijing, China.

Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly causes systematic and irreparable damage to targeted cells, has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies. As the Food and Drug Administration (FDA) approvals of [Lu]Lu-DOTA-TATE, [Lu]Lu-PSMA-617 and their complementary diagnostic agents, namely, [Ga]Ga-DOTA-TATE and [Ga]Ga-PSMA-11, targeted radiopharmaceutical-based theranostics (radiotheranostics) are being increasingly implemented in clinical practice in oncology, which lead to a new era of radiopharmaceuticals.

View Article and Find Full Text PDF

In the post-COVID-19 era, drug-resistant bacterial infections emerge as one of major death causes, where multidrug-resistant Acinetobacter baumannii (MRAB) and drug-resistant Pseudomonas aeruginosa (DRPA) represent primary pathogens. However, the classical antibiotic strategy currently faces the bottleneck of drug resistance. We develop an antimicrobial strategy that applies the selective delivery of CRISPR/Cas9 plasmids to pathogens with biomimetic cationic hybrid vesicles (BCVs), irrelevant to bacterial drug resistance.

View Article and Find Full Text PDF

The gluteus medius allows hip abduction and stabilization of the pelvis when walking. A rupture of the gluteus medius tendon is associated with lateral hip pain, weakness, a positive Trendelenburg sign, and a limp. Diagnosis is confirmed by ultrasound or MRI.

View Article and Find Full Text PDF

Osteochondral lesions of the talus (OLTs) should initially be treated nonoperatively. In case of failure of a large, irreparable (nonprimary) OLT, osteochondral transplantation techniques may be recommended. Harvesting an osteochondral graft from the ipsilateral knee is most commonly used.

View Article and Find Full Text PDF
Article Synopsis
  • Platelet transfusions can transmit infections, but the Mirasol Pathogen Reduction Technology uses riboflavin and UV light to make platelets safer by inactivating pathogens and white blood cells.
  • This study reviewed the safety of Mirasol PRPTs given to critically ill infants in a NICU in Curaçao, covering data from February 2016 to April 2023.
  • Out of 208 PRPTs given to 46 infants, no significant complications were observed, and although 46% of patients died during the study, these deaths were not associated with the transfusions, indicating that Mirasol PRPTs are safe for use in critically ill neonates.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!